Compare Biogen Inc (BIIB) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Alphabet Inc Class A — how do they compare? Biogen Inc trades at $193.42 (market cap $28.34B), while Alphabet Inc Class A trades at $367.47 (market cap $4.37T). The key difference: Alphabet Inc Class A is far larger — about 154.2× Biogen Inc's market cap, and Alphabet Inc Class A pays a 0.24% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | GOOGL | |
|---|---|---|
Market Cap | $28.34B | $4.37T |
Sector | Health | Media |
52-Week High | $216.63 | $402.62 |
52-Week Low | $122.68 | $182.00 |
Enterprise Value | $30.62B | $4.34T |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Alphabet (GOOGL) trades at $367.14, up 4.15% today, with a neutral technical signal and strong fundamentals. The stock shows robust profitability with a 37.92% net margin and consistent earnings beats, including Q1 2026 EPS of $5.11 versus $2.64 expected. Revenue grew to $402.84B in 2025, and operating cash flow surged to $164.71B. Analysts are overwhelmingly bullish with an 85.19% buy rating and a $431.78 consensus price target. Recent news highlights AI-driven growth opportunities, including partnerships and YouTube subscription price increases.
The outlook for GOOGL remains positive, supported by AI expansion and solid financials, but risks include antitrust scrutiny and market volatility. The stock offers upside to analyst targets, though investors should monitor competitive pressures and regulatory developments that could impact growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
